|Factors affecting the 6-month functional response to ChEI treatment (final general linear models)|
|Dependent variable, change from baseline||IADL||PSMS|
|Percentage of variance accounted for||R2= 0.310,p< 0.001||R2= 0.335,p< 0.001|
|Significant predictors||β||95% CI (β)||pvalue||β||95% CI (β)||pvalue|
|Intercept||−10.922||−15.585, –6.259||< 0.001||0.419||−2.156, 2.995||0.749|
|Age at first assessment, years||−0.041||−0.070, –0.011||0.007||−0.018||−0.036, –0.001||0.036|
|ADL score at baselinea||0.521||0.300, 0.741||< 0.001||−0.175||−0.441, 0.090||0.196|
|MMSE score at baseline||0.453||0.267, 0.640||< 0.001||−0.021||−0.128, 0.086||0.697|
|Number of medications at baseline||ns||−0.079||−0.134, –0.024||0.005|
|NSAIDs/Acetylsalicylic acid (no = 0, yes = 1)||ns||0.419||0.133, 0.705||0.004|
|ADL baseline scorea × MMSE baseline score||−0.016||−0.026, –0.006||0.002||0.018||0.005, 0.032||0.008|
Gender, APOE ε4 carrier status, solitary living, age at onset (or duration of AD), years of education and the variables comparing the ChEI agents and dose were not significant.
β values are expressed per 1 unit increase for continuous variables and for the condition present in dichotomous variables
aADL = IADL or PSMS, respectively.
ChEI cholinesterase inhibitor, CI confidence interval, IADL Instrumental Activities of Daily Living scale, MMSE Mini-Mental State Examination, NSAID non-steroidal anti-inflammatory drugs, ns not significant, PSMS Physical Self-Maintenance Scale.
Wattmo et al. BMC Neurology 2012 12:134 doi:10.1186/1471-2377-12-134